In May 2022, tirzepatide was first authorized to treat T2DM in the United States
Glucagon-like peptide-1 (GLP-1) is mainly produced by cells in the intestines and neurons in the hindbrain nucleus tractus solitarius in response to food intake
As the newest addition to incretin-based drugs, tirzepatide harbors the potential to counteract most of the pathogenetic mechanisms underpinning CKD in T2D displaying unprecedented features in terms of glucose and weight lowering, accompanied by promotion of insulin sensitivity, control of SBP, dyslipidemia, and biomarkers of inflammation and endothelial dysfunction
What Happens During Treatment
Selank An anxiolytic and nootropic peptide that modulates GABA and serotonin pathways
Follow-up should assess shedding, density, calibre, miniaturization, weight trajectory, nutritional status and response to medical management